Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STI-2099
- Development stage
- Phase 2
- Lead developer
- Sorrento Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intranasal
01
Overview
COVI-DROPS (STI-2099) is an investigational intranasal formulation of a neutralizing monoclonal antibody developed for the treatment of COVID-19. It is designed to be administered as nasal drops to recently infected patients with asymptomatic or mild COVID-19. The drug utilizes the same neutralizing antibody substance as Sorrento’s intravenous formulation (COVI-AMG), targeting the SARS-CoV-2 virus and its variants of concern, including Alpha and Delta. The mechanism involves direct binding and neutralization of SARS-CoV-2 in the nasal mucosa, aiming to prevent viral progression and severe disease. Developed by Sorrento Therapeutics, it has undergone Phase 1 safety studies in healthy volunteers and entered Phase 2 efficacy trials in outpatients with COVID-19 in multiple countries[1][4][5].
- Brand names
- COVI-DROPS
- Other names
- COVI-DROPSSTI-2099STI2099STI 2099
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on STI-2099.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STI-2099.